Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

34.02 -0.59 (-1.69%)
Streaming Delayed Price Updated: 10:47 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Assembly Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Assembly Biosciences' Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants ↗
Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent genital herpes. The drug showed a favorable safety profile and achieved... 
Via Benzinga
News headline image
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
ASMB Stock Earnings: Assembly Biosciences Beats EPS, Beats Revenue for Q2 2024 ↗
ASMB stock results show that Assembly Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Insiders Buying American Software And 2 Other Stocks ↗
 
Via Benzinga
News headline image
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with interim data expected by the end of 2024 – 
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Announces $12.6 Million in Equity Financings
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q1 2024 ↗
ASMB stock results show that Assembly Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q4 2023 ↗
ASMB stock results show that Assembly Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
ASMB Stock Earnings: Assembly Biosciences Misses EPS for Q2 2023 ↗
ASMB stock results show that Assembly Biosciences missed analyst estimates for earnings per share the second quarter of 2023. 
Via InvestorPlace
News headline image
Assembly Biosciences Announces Effective Date of Reverse Stock Split
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Provides Anticipated Development Milestones for 2024
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket ↗
Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
From Assembly Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.